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Abstract
Thromboxane synthase (TXAS) and thromboxane A2 receptor (TP), two critical components for thromboxane A2 (TXA2)
signaling, have been suggested to be involved in cancer invasion and metastasis. However, the mechanisms by which TXA2
promotes these processes are still unclear. Here we show that TXA2 mimetic, I-BOP, induced monocyte chemoattractant
protein -1(MCP-1)/chemokine (C-C motif) ligand 2 (CCL2) expression at both mRNA and protein levels in human lung
adenocarcinoma A549 cells stably over-expressing TP receptor a isoform (A549-TPa). The induction of MCP-1 was also found
in other lung cancer cells H157 and H460 that express relatively high levels of endogenous TP. Using specific inhibitors of
several signaling molecules and promoter/luciferase assay, we identified that transcription factor SP1 mediates I-BOP-
induced MCP-1 expression. Furthermore, supernatants from I-BOP-treated A549-TPa cells enhanced MCP-1-dependent
migration of RAW 264.7 macrophages. Moreover, co-culture of A549 cells with RAW 264.7 macrophages induced expression
of MMPs, VEGF and MCP-1 genes, and increased the invasive potential in A549 cells. These findings suggest that TXA2 may
stimulate invasion of cancer cells through MCP-1-mediated macrophage recruitment.
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Introduction
There is overwhelming evidence showing that chemokines play
a significant role in tumor progression, especially in cancer
invasion and metastasis [1]. Chemokines are a superfamily of
biologically active peptides which comprises about 50 members so
far. Among these many chemokines monocyte chemoattractant
protein -1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2), a
member of the CC chemokines subfamily, is of particular
relevance to cancer invasion and metastasis. MCP-1 is over-
expressed in a variety of cancer types including glioma, ovarian,
lung, breast and prostate cancer [2–4]. As its name indicates,
MCP-1 is a potent chemoattractant for monocytes/macrophages.
It has been demonstrated that MCP-1-mediated macrophage
infiltration promotes tumor progression in various types of cancer.
For example, MCP-1 secreted by breast tumor cells recruits
inflammatory monocytes that produce VEGF to promote tumor
cells extravasation and lung metastasis [5,6]. MCP-1 also enhances
prostate tumor growth and angiogenesis by recruitment of
monocytes and tumor associated macrophages (TAMs) into the
tumor microenvironment [7]. In addition, tumor cells derived
from renal cancer recruit tumor-infiltrating lymphocytes (TIL) by
secreting MCP-1 and IL-8 which contribute to renal cancer
progression [8]. Moreover, CC chemokines including MCP-1 and
MIP-1b were found to be associated with macrophage infiltration
in human non-small cell lung cancer (NSCLC) tumors. Patients
with recurrence of the disease were found to have higher
macrophage infiltration in their initial tumors [9]. In addition to
tumor cells themselves, tumor associated stromal cells such as
endothelial cells, fibroblasts and macrophages also produce a
significant amount of MCP-1 to increase TAM infiltration and
maintain inflammation, therefore, promoting tumor progression
[10,11].
MCP-1 can be induced by a variety of growth factors and
cytokines, such as platelet-derived growth factor (PDGF) [12],
tumor necrosis factor alpha (TNFa) [13], interferon gamma (IFN-
c) [14], and IL-1b [15]. Recent studies have found that
arachidonate metabolites, prostaglandin E2 (PGE2) and 15(S)-
HETE also induce the expression of MCP-1 [16,17]. Blockade of
thromboxane A2 (TXA2) receptor (TP) suppressing the expression
of MCP-1 in human umbilical vein endothelial cells has been
reported as well [18]. However, whether activation of TP can
induce MCP-1 expression and release from cancer cells remains to
be determined.
TXA2 is generated from prostaglandin H2 (PGH2) by the action
of thromboxane synthase (TXAS) [19]. Levels of TXAS have been
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reported to correlate with the invasion and metastasis potential of
cancer cells [20–22]. TXA2 mimetic, U46619, was also found to
stimulate the invasion of bladder cancer cells [23]. Nonetheless,
the critical molecules that mediate TXA2-stimulated invasion and
progression of cancer cells need to be identified.
We recently reported that TP agonist, I-BOP, induced A549-
TPa cells invasion via induction of several MMPs [24]. In the
current study, we show that I-BOP also induced the expression of
MCP-1 in A549-TPa cells which exhibited a chemotactic effect on
RAW 264.7 macrophages. Co-culture of A549 cells or A549-TPa
cells with RAW 264.7 macrophages also increased the expression
of MMPs, VEGF andMCP-1 genes, and the invasion by A549 cells.
These findings suggest that MCP-1 is an important mediator for
TXA2-stimulated invasion of cancer cells.
Materials and Methods
Reagents
I-BOP, SQ29548, PGD2, PGE2, PGF2a were from Cayman
Chemical (Ann Arbor, MI). GF109203X was from Calbiochem
(San Diego, CA). U0126 was from Alexis Biochemicals (San
Diego, CA). RS-102895, mithramycin A, geldanamycin and other
biochemicals and chemicals were from Sigma-Aldrich (St. Louis,
MO). Recombinant human MCP-1 and polyclonal antibody
directed against MCP-1 and characterized for neutralizing activity
were from PeproTech (Rocky Hill, NJ). Antibodies against SP1
and E-cadherin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Antibody against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was generated in house as previously
described [25].
Cell Lines and Cell Culture
Human lung adenocarcinoma cell line A549 overexpressed TPa
or TPb and the control A549 cells overexpressed GFP were
established and identified as previously described [24]. These cells
were designated as A549-TPa, A549-TPb and the control A549
cells accordingly. All these cells and other two lung cancer cell
lines H157 and H460 were maintained in RPMI1640 medium
supplement with 10% heat inactivated fetal bovine serum (FBS),
0.1 mg/mL streptomycin and 100 U/mL of penicillin G (Invitro-
gen, Carlsbad, CA) at 37uC in a humidified atmosphere of 95% air
and 5% CO2. Mouse Raw 264.7 macrophages were maintained in
Dulbecco’s modified Eagle’s medium (DMEM). All cells were
originally obtained from the American Type Culture Collection
(ATCC; Manassas, VA).
Cell Treatment and Western Blot
Cells were plated in 12-well plates to achieve ,80% confluence
next day, and then were starved in RPMI 1640 medium without
FBS for 24 h before stimulation. For inhibition study, cells were
pretreated with the respective inhibitors at working concentrations
for 30 min in serum-free medium prior to stimulation. After a
certain time of treatment, cells or cultured media were collected
for Western blot analysis as described previously [26]. Intensities of
Western blot bands were quantified using NIH Image J software.
MCP-1 Precipitation
MCP-1 in cell culture media was precipitated by using
trichloroacetic acid (TCA)-acetone method. Briefly, TCA was
added to media at a final concentration of 10%. Proteins were
precipitated for 4 h on ice. Precipitated proteins were centrifuged
at 5,0006g for 30 min, washed three times in cold acetone, and air
dried. Total protein was quantified by the Bio-Rad protein assay
(Bio-Rad Laboratories, Inc., Hercules, CA) to ensure equal
loading of proteins for Western blot analysis.
Reverse Transcription-polymerase Chain Reaction (RT-
PCR)
Total RNA was isolated from cells using the TRI Reagent
(Sigma-Aldrich, St. Louis, MO) and reverse transcribed using the
SuperScript II reverse transcriptase (Invitrogen, Calsbard, CA).
The PCR primers for MCP-1 gene amplification were 59-ATAGC
AGCCACCTTCATTCC-39 (forward) and 59-TTCCCCAAG
TCTCTGTATCT-39(reverse); for MMP-1 were 59-CATTGAT
GGCATCCAAGC-39(forward) and 59-CCGGACTTCATCTC
TGT-39(reverse); for MMP-9 were 59-GGCGCTCATGTACCC-
TATGT-39(forward) and 59-TCAAAGACCGAGTCCAGCTT-
39 (reverse); for MMP-10 were 59-GTCACTTCAGCTCCT
TTCCT-39(forward) and 59-ATCTTGCGAAAGGCGGAACT-
39(reverse); for MMP-13 were 59-AGTGGTAAGAATAGTA-
GATGTG-39(forward) and 59-GGCCGATCATATATTCAA-
TAAGT-39(reverse); for VEGF 59-GGATGTCTATCAGCG-
CAGCTAC-39(forward) and 59-TCACCGCCTCGGCTTGTC
ACATC-39(reverse); for b-actin 59-GGCATGGGTCAGAAG-
GATTCC-39(forward) and 59-AGCACAGCCTGGATAGCAA
CG-39(reverse). PCR conditions were 2 min at 95uC followed by
35 cycles (23 cycles for MCP-1 and b-actin) of 95uC for 1 min, 50–
60uC for 30 s and 72uC for 1 min. The PCR product of each
sample was analyzed by electrophoresis in a 1.5% agarose gel and
visualized by ethidium bromide staining.
Real-time PCR Analysis of MCP-1 mRNA
The real-time PCR was performed with human MCP-1 and b-
actin (as an internal standard)-specific primers. The sequence of
the MCP-1 forward primer was 59-ATAGCAGCCACCTT-
CATTCC-39, and the sequence of MCP-1 reverse primer was
59-ATCCTGAACCCACTTCTGCT-39. The sequence of b-actin
forward primer was 59-AGAAAATCTGGCACCACACC-39, and
the sequence of b-actin reverse primer was 59-AGAGGCGTA-
CAGGGATAGCA-39. All real-time PCR reactions were carried
out in a final volume of 50 ml and were performed in duplicate for
each cDNA sample in the ABI PRISM 7700 Sequence Detection
System according to the manufacturer’s protocol. The optimized
reaction consisted of 25 ml of iTaq SYBRGreen Supermix with
ROX, 0.02 U/ml of Uracil-N-glycosylase, 3 ml of diluted cDNA
templates, and 200 nM of each specific forward and reverse
primer. The PCR protocol was 95uC for 5 min, followed by 45
cycles of 95uC for 15 s and 60uC for 1 min. Specificity of the
amplification was checked by melt-curve analysis. Relative levels
of mRNA expression were calculated according to Pfaffl method
[27]. Individual expression values were normalized by comparison
with b-actin mRNA expression.
Promoter Construct and Site-directed Mutagenesis
Human MCP-1-CAT reporter plasmid was kindly provided by
Dr. Bassel E. Sawaya (Temple University, Philadelphia, PA) and
reconstructed into pGL3 luciferase reporter vector. A site-directed
mutagenesis kit (Stratagene, La Jolla, CA) was used to mutate the
core sequence of SP1 binding site in the reconstructed luciferase
reporter plasmid; SP1 wild-type (SP1wt), 59-CCGCCC-39 and
SP1 mutant (SP1m), 59-CCGggg-39.
Luciferase Assay
Cells were seeded in 12-well plates and transfected with pGL3-
MCP-1 reporter plasmids using TransIT-2020 Transfection
Reagent (Mirus Bio LLC, Madison, WI). After 24 h of transfec-
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tion, cells were incubated with I-BOP or control (0.1% ethanol) for
additional 18 h. Thereafter, cells were collected and further
detected by using a microplate luminometer (MTX lab systems,
Vienna, VA). The luciferase activity in cell lysate was determined
as described previously [25].
Preparation of Nuclear Extract
Nuclear proteins were prepared as described previously [28]. In
brief, A549-TPa cells were scraped into cold phosphate buffered
saline (PBS) and centrifuged at 1000 rpm for 2 min. Pellets were
resuspended in buffer A [10 mM HEPES-KOH pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol (DTT) and 0.2 mM
phenylmethylsulfonyl fluoride (PMSF)] and incubated on ice for
15 min, then centrifuged at full speed in a tabletop centrifuge. The
nuclear pellets were lysed for 20 min on ice in buffer B (20 mM
HEPES-KOH, 1.5 mM MgCl2, 420 mM NaCl, 25% glycerol,
0.2 mM EDTA, 0.5 mM DTT and 0.2 mM PMSF), and
centrifuged for 2 min as above. The supernatant containing
nuclear proteins was frozen at 280uC until analyzed.
Preparation of Conditioned Medium
A549-TPa cells were plated into 10 cm dishes to achieve ,80%
confluence next day, then media were switched to 10 ml serum
free RPMI1640. After 24 h of starvation, cells were treated with
vehicle (0.1% ethanol) or I-BOP (50 nM) in fresh serum free
medium for another 24 h. Then, conditioned medium was
collected and passed through 30 kDa and 10 kDa cutoff centrif-
ugal filters (Millipore, Billerica, MA) sequentially (MCP-1 molec-
ular weight is 13–15 kDa). The remains on 10 kDa filter were
dissolved in 1.5 ml serum free medium and stored at 280uC until
used.
Macrophage Migration Assay
RAW 264.7 macrophages migration was assessed by using
CytoSelect 96-well cell migration assay kit (Cell Biolabs, San
Diego, CA) following the manufacturers instruction. In brief,
,1.06105 cells in serum free medium were seeded onto the top
well of a Trans-well insert (8 mm polycarbonate nucleopore filters),
and the bottom well was supplemented with 150 ml serum free
medium or A549-TPa conditioned medium prepared above. After
12 h of stimulation, cells that had migrated through the filter were
detached and dyed with CyQuant GR dye solution. The
fluorescence was measured at 480/520 nm. For antibody neutral-
ization study, 150 ml serum free medium or conditioned medium
was incubated with MCP-1 neutralizing antibody (5 mg) or isotype
control antibody (5 mg) for 2 h at 37uC before added to the lower
chamber. For inhibition study, RAW 264.7 cells were incubated
with MCP-1 receptor (CCR2) antagonist RS-102895 (10 mM) for
30 min before stimulation with the conditioned medium.
Co-culture Experiments
For transwell co-culture system, control A549 or A549-TPa
cells were plated into a six-well culture plate, and RAW 264.7 cells
were seeded onto transwell inserts (with a 0.4 mm pore size) top on
another six-well plate. After 24 h, the media of A549 and RAW
cells were replaced with fresh serum free media and the RAW
264.7 transwell inserts were moved onto the six-well plate where
A549 cells were seeded. After 12 h of co-culture, A549 cells were
pictured and collected for RT-PCR analysis. For direct co-culture,
control A549 cells which express GFP were plated with or without
RAW 264.7 cells into a 12-well plate and cells were pictured after
a certain periods. The images of cells were captured using a Kodak
digital camera under Olympus Tokyo CK inverted microscope.
Invasion Assay
The invasion assay was carried out following the instructions of
Cultrex 24-well Transwell BME cell invasion assay (Trevigen).
Briefly, a 24-well unit with 8 mm polycarbonate nucleopore filters
(Corning) evenly coated with 100 ml basement membrane extract
coating solution (Trevigen) at 37uC for 4 h. Control A549 cells
(26105) expressing GFP and RAW 264.7 macrophages (16105) in
serum free medium were placed in the upper compartment, and
50% RPMI 1640 plus 50% DMEM medium supplied with 0.5%
FBS was added to the lower compartment. After 24 h incubation,
cells that had not invaded were removed with a cotton swab. Cells
that had invaded the lower surface of the membrane were
observed under a fluorescence microscope. Invaded cells in three
randomly selected fields were counted.
Statistical Analysis
The differences between each group were expressed as mean 6
SD. Statistical significance was assessed by Student’s t test.
Differences were considered statistically significant when P values
were #0.05.
Results
Induction of MCP-1 Expression by Activation of TP
To examine the effects of activation of TPa on the expression of
MCP-1, A549-TPa cells were treated with TP agonist I-BOP
(50 nM) at different time points. RT-PCR results showed that I-
BOP induced a rapid and sustained expression of MCP-1 mRNA
(Figure 1A). Quantitative real-time PCR assay was utilized to
further determine the kinetics of MCP-1 induction. As shown in
Figure 1B, the MCP-1 mRNA levels peaked at 4 h and still
maintained a significant increase at 16 h after I-BOP treatment.
The protein levels of I-BOP-induced MCP-1 expression were
analyzed by Western blot assay. The accumulation of MCP-1 in
conditioned medium reached the maximum level at 24 h following
stimulation (Figure 1C). The induction of MCP-1 by I-BOP was
dose-dependent and the effect was significant even at 1 nM of I-
BOP (Figure 1D). In addition, I-BOP-induced MCP-1 expression
can be observed in A549-TPb but not in control A549 cells
indicating both TPa and TPb mediate MCP-1 expression
(Figure 1E). Further, the induction of MCP-1 by I-BOP was also
observed in H157 and H460 human lung cancer cells that express
relatively high endogenous levels of TP [29] (Figure 1F). When
compared with other prostanoids including PGD2, PGE2, and
PGF2a, which were all used at their optimal concentrations, I-BOP
induced the most significant expression of MCP-1 in A549-TPa
and H460 cells (Figure 1G). These data show that TP plays an
important role in the production of MCP-1 in lung cancer cells.
SP1 is Important for TPa-mediated MCP-1 Expression
Upon ligand binding, TP activates several downstream signal
transduction cascades including PKC, and ERK pathways that are
involved in cytokine-induced MCP-1 expression [15,25,30,31]. To
investigate whether these pathways are responsible for I-BOP-
induced MCP-1 expression, several specific inhibitors were used.
These inhibitors were used at concentrations proven to be optimal
for each signaling molecule as described previously [25]. As shown
in Figure 2A, except TP antagonist, SQ29548 at 10 mM, none of
other inhibitors (0.5 mM GF109203X for PKC and 10 mM U0126
for MEK/ERK) has an effect on I-BOP-induced MCP-1
expression indicating these pathways are not involved in the
induction. In the proximal region of MCP-1 promoter, there is a
GC rich element, which can bind nuclear factor SP1 to activate
transcription [12]. To elucidate whether SP1 is critical for MCP-1
TP-Mediated Macrophages/Cancer Cells Interaction
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induction by I-BOP, we employed mithramycin A (MTM), a
specific SP1 inhibitor preventing SP1 from binding to its consensus
GC rich sites [32], and geldanamycin (GA), an inhibitor of Hsp90
which was also reported to affect binding of SP1 to gene promoter
[33]. Both inhibitors significantly suppressed the induction of
MCP-1 by I-BOP at protein and mRNA levels (Figure 2B and C).
We further investigated the effects of I-BOP on SP1 translocation
and expression. As shown in Figure 2D, SP1 protein started to
accumulate in the nucleus after incubation with I-BOP for 30 min,
and remained elevated at 4 h. I-BOP also induced the expression
of SP1 at 2 h. Moreover, promoter-luciferase reporter bearing a
fragment of 500 bp of human MCP-1 gene promoter was used to
evaluate the contribution of SP1 to I-BOP-induced MCP-1
transcription. SP1-binding element is located at 2115 bp of
MCP-1 promoter. Site-directed mutagenesis of SP-1 site resulted
in a significant decrease of I-BOP-induced promoter activity
compared with the wild type (Figure 2E). These data reveal that
TP-mediated MCP-1 expression is SP1 dependent.
Figure 1. Effects of I-BOP on MCP-1 expression. A I-BOP induced transcription of MCP-1. Cells were serum-starved for 24 h before treated with
50 nM I-BOP for the indicated time periods. RNAs were isolated and RT-PCR was carried out as described in Materials and methods. B MCP-1 mRNA
induction in A was confirmed by quantitative real-time PCR. **p,0.01 compared with untreated cells. C Time-dependent effects of I-BOP on MCP-1
protein expression. After 24 h serum-starvation, cells were treated with 50 nM I-BOP for the indicated time periods. Media were collected and
proteins in each medium were concentrated by trichloroacetic acid (TCA) precipitation as described in Materials and methods. Concentrated samples
were quantified by Bio-Rad protein assays to ensure equal protein loading for Western blot analysis. D Dose-dependent effects of I-BOP on MCP-1
protein expression in A549-TPa cells. E I-BOP-induced MCP-1 protein expression in A549-TPb not A549-GFP cells. F I-BOP-induced MCP-1 protein
expression in H157 and H460 cells. G Comparison of I-BOP with other prostanoids on the induction of MCP-1 in A549-TPa and H460 cells. Cells were
treated with 50 nM I-BOP, 1 mM PGD2, 1 mM PGE2 or 1 mM PGF2a for 24 h. The concentrations of prostanoids used here were optimized to induce the
most expression of MCP-1. Media were collected and assayed as described in C. Densitometric analysis of each band was made, and control untreated
time point is normalized to 1. All data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0054073.g001
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I-BOP-induced MCP-1 Exhibits Chemotactic Effects on
Macrophages
To determine the chemotactic property of I-BOP-induced
MCP-1 on macrophages, we examined the effect of conditioned
medium from A549-TPa cells treated with or without I-BOP on
the migration of murine macrophage RAW 264.7 cells. As shown
in Figure 3A, conditioned medium from I-BOP-treated cells
significantly induced RAW 264.7 cell migration compared to the
Figure 2. I-BOP regulates MCP-1 expression in SP1-dependent manner. A Effects of TP antagonist and several protein kinases inhibitors on
MCP-1 induction by I-BOP stimulation. Cells were treated with TP antagonist SQ29548 (10 mM), PKC inhibitor GF109203X (0.5 mM), and MEK inhibitor
U0126 (10 mM) for 30 min before incubation with 50 nM I-BOP for 24 h. Media were collected and assayed as described in Fig. 1C. B Effects of SP1
inhibition on I-BOP-induced MCP-1 expression at protein levels. Cells were treated with indicated concentrations of SP1 inhibitor mithramycin A
(MTM) and Hsp90 inhibitor geldanamycin (GA) for 30 min before incubation with 50 nM I-BOP for 24 h. Media were collected and assayed as
described in Fig. 1C. C Effects of SP1 inhibition on I-BOP-induced MCP-1 expression at mRNA levels. Cells were treated with above inhibitors for
30 min before incubation with 50 nM I-BOP for 4 h. RNAs were isolated and real-time PCR was performed as described in Materials and methods.
*p,0.05 and **p,0.01 compared with I-BOP treated alone. D Protein level of SP1 was increased in the nuclei of A549-TPa cells following I-BOP
stimulation. Cells were treated with 50 nM I-BOP for the indicated time periods. Nuclear extract and whole cell lysate were prepared as described in
Material and methods. Protein level of SP1 was determined by Western blot. Densitometric analysis of each band was made and control untreated
time point was normalized to 1. E Regulation of MCP-1 promoter activity by SP1. A549-TPa cells were transfected with luciferase reporter plasmids
containing 500 bp of MCP-1 promoter sequence with either wild type or mutated SP1 binding sites. After 24 h transfection, cells were treated with
vehicle control (0.1% ethanol) or 50 nM I-BOP for additional 18 h in serum free medium. Luciferase assay was carried out as described in Materials and
methods. **P,0.01. All data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0054073.g002
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medium from vehicle (0.1% ethanol)-treated cells. MCP-1
neutralizing antibody and RS-102895, an antagonist of CCR2,
significantly decreased the chemotactic potency of medium from I-
BOP-treated A549-TPa cells suggesting that MCP-1 in the
medium might be responsible for the effect. Indeed recombinant
MCP-1 which was used as a positive control showed strong
chemotactic effects on RAW 264.7 cells as expected (Figure 3B).
These data indicate that MCP-1 is a key chemotactic factor in
A549-TPa cell culture which caused migration of macrophages.
Co-culture of RAW 264.7 Macrophages Induces
Expression of Metastatic Genes by A549 Cells
To elucidate the effects of macrophages on the invasiveness of
A549 cells, we first used a trans-well co-culture system as shown in
Figure 4A. In this co-culture system, there is no cell-cell direct
contact and cells communicate with each other through soluble
proteins. Both control A549 and A549-TPa cells became more
elongated and scattered after 12 h of co-culture with RAW 264.7
cells than the cells grown alone (Figure 4B). Furthermore, results
from RT-PCR analysis showed that expression of metastatic genes
including several MMPs and VEGF were significantly elevated in
either control A549 or A549-TPa cells co-cultured with macro-
phages (Figure 4C). Macrophages also induced MCP-1 gene
expression by control A549 or A549-TPa cells (Figure 4C). E-
cadherin-catenin complex is critical for cell adhesiveness and
maintenance of normal tissue architecture. Reduction of E-
cadherin is tightly linked with cell migration and invasion
[34,35]. Therefore, we examined whether macrophage-lung
cancer cell interactions regulate E-cadherin expression in control
A549 or A549-TPa cells. Indeed, co-culture with RAW 264.7
macrophages significantly reduced the levels of E-cadherin in
either type of A549 cells (Figure 4D). All of these results were
reproducible in wild type A549 cells without GFP or TPa
expression (data not shown). Collectively, these data indicate that
co-culture with macrophages may increase migration and invasion
potential of A549 cells.
Figure 3. Chemotactic effects of A549-TPa conditioned media and MCP-1 on RAW 264.7 macrophages. A. Conditioned media increased
the chemotaxis of RAW cells via MCP-1. CM-C is derived from vehicle-treated cells, and CM-I is derived from I-BOP-treated cells. SFM represents serum
free medium. The concentrations of anti-MCP-1 antibodies and isotype control IgG were each at 5 mg/ml original CM. The concentration of RS-102895
was 10 mM. Detailed conditions were as described in Materials and Methods. **P,0.01. B Effect of recombinant MCP-1 on the chemotaxis of RAW
cells. MCP-1 at 1, 10 and 100 ng/ml were tested as described in Materials and methods.
doi:10.1371/journal.pone.0054073.g003
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Co-culture of RAW 264.7 Macrophages Induces
Morphological Change and Invasion of A549 Cells
To further examine if macrophages promote invasion of A549
cells, we next used another co-culture system as shown in Figure 5A.
In this system, cells communicate with each other via direct contact,
which is closer to the physiological situation. As shown in Figure 5B,
after 12 h of co-culturewithmacrophages, control A549 cells exhibit
elongated protrusions indicating the invasion potential. This
morphology still sustained after 36 h of co-culture. In addition, in
matrigel invasion assay, co-culture withmacrophages induced a 2.5-
fold increase in cellular invasiveness of control A549 cells through
matrigel relative to those cells grown alone (Figure 5C). These results
Figure 4. Transwell co-culture of RAW 264.7 macrophages induces metastatic gene expression by A549 cells. A A transwell co-culture
system of RAW 264.7 macrophages and A549 cells was used in this study. RAW 264.7 cells and A549 cells were separately cultured for 24 h and then
co-cultured in serum free medium for further 12 h or 24 h as described in Materials and methods. B Control A549 and A549-TPa cells became more
scattered and spindle shaped after culture with RAW 264.7 cells. Both types of A549 cells were pictured after 12 h of culture with or without RAW
264.7 cells as described in A. C Co-culture of RAW 264.7 macrophages induced metastatic gene expression by A549 cells. After 12 h of co-culture with
macrophages, the expression of several metastatic genes in control A549 and A549-TPa cells, including MMPs, VEGF and MCP-1 mRNA, were
examined by RT-PCR as described in Materials and methods. D Co-culture of RAW 264.7 macrophages decreased E-cadherin expression by A549 cells.
Control A549 and A549-TPa cells were collected after 24 h of culture with or without RAW 264.7 cells as described in A. Protein level of E-cadherin
was determined by Western blot as described in Material and methods. All data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0054073.g004
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indicate that macrophages attracted by MCP-1 released from A549
cells may stimulate cancer cells invasion.
Discussion
The relationship between over-expression of TXAS or TP, two
necessary components for TXA2 production and function, and
cancer invasion and metastasis was observed in a wide range of
cancers including NSCLC [36,37]. However, there are few studies
revealing the downstream targets by which TXA2-TP signaling
axis mediates these processes. In the present study, we identified
chemokine MCP-1 as an important product of TP signaling in
lung cancer A549 cells expressing TPa ectopically. Our findings
suggest that MCP-1 may attract macrophages to cancer cells,
thereby promoting their invasion.
Figure 5. Direct co-culture of RAW 264.7 macrophages induces morphological change and invasion of A549 cells. A. A direct co-
culture system of RAW 264.7 macrophages and A549 cells was used in this study. RAW 264.7 cells and A549 cells were plated into the same well of a
culture plate. B. A549 cells exhibit elongated shape after culture with RAW 264.7 macrophages. The control A549 cells were plated into a 12-well
plate with or without RAW 264.7 cells as described in A. Cells were pictured at the indicated time points. In the lower panel, those small cells
exhibiting round shape were RAW 264.7 cells. C. Co-culture of RAW 264.7 macrophages induced invasion of A549 cells. Invasion assay of A549 cells
was carried out as described in Material and methods. **P,0.01. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0054073.g005
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TXA2 has been shown to induce MCP-1 expression in vascular
endothelial cells and also other cytokines in WISH cells (an
amnion epithelium-derived cell line) [18,38]. In addition, a recent
report showed that TXAS inhibitor ozagrel suppressed MCP-1
and IL-8 gene expression and inflammatory cell accumulation in a
lung injury model indicating the role of TXA2 in regulation of
these processes [39]. Cancers and chronic inflammation display
significant parallels. Therefore, they share certain characteristics.
Several CC chemokines including MCP-1 were found to be highly
expressed in human NSCLC tumor tissues and the levels of MCP-
1 also significantly correlated to macrophage infiltration [9]. These
findings have prompted us to hypothesize that TXA2 might be
involved in lung cancer development via MCP-1-mediated
macrophage recruitment.
Mechanisms of regulation of MCP-1 by I-BOP were further
studied. There are several cis-acting transcriptional regulatory
elements including AP1 and SP1 sites in the promoter region of
human MCP-1 gene. Activation of AP-1 by TP-mediated G
protein signaling has been found in several other cell types
including A549 cells [25]. We previously found that I-BOP-
induced MMP-1 expression was mediated by PKC and ERK-
dependent AP-1 activation in the same cell lines [24]. Neverthe-
less, inhibition of ERK and PKC did not block I-BOP-induced
MCP-1 expression, suggesting AP-1 was not involved in MCP-1
regulation by I-BOP in A549-TPa cells. These data indicated that
separate signaling pathways were involved in the expression of
downstream targets induced by I-BOP activation of TP. It is also
possible that MCP-1 regulation is tissue-specific. AP-1 is not
important for MCP-1 expression in lung epithelial cancer cells. A
separate study in fibroblast 3T3 cells showing that the expression
of MMP-1 induced by growth factors was c-Fos-dependent,
whereas that of MCP-1 was not provides support to our
proposition [40]. Moreover, it has been reported that PDGF
induction of MCP-1 transcription requires SP1 but not AP-1
response elements in its promoter region in fibroblast [12].
Therefore, we propose that in lung cancer cells I-BOP may
regulate MCP-1 expression in a way similar to how PDGF does in
fibroblast. We observed that SP1 was increased in the nucleus after
I-BOP stimulation and SP1 inhibitor blocked I-BOP-induced
MCP-1 expression. Furthermore, using GC-rich promoter region
of 12(S)-lipoxygenase as a probe, Chang and his colleagues
identified that Hsp90 interacts with SP1 and modulates its
promoter binding ability [33]. In the present study, indirect
inhibition of SP1 by Hsp90 inhibitor geldanamycin blocked I-
BOP-induced MCP-1 expression at protein as well as mRNA
levels. Moreover, the results obtained from MCP-1 promoter-
luciferase reporter assay further indicate the critical role of SP1
binding site in MCP-1 regulation by I-BOP. Although the
upstream signals by which TP regulates SP1 expression and
translocation need further studies, the results presented here
demonstrated that I-BOP induced MCP-1 expression in A549-
TPa cells by SP1-dependent but AP-1-independent mechanism.
It has been shown that the increased accumulation of
macrophages in the tumor microenvironment was associated with
poor prognosis of several types of cancers such as prostate, breast,
bladder, and esophageal cancers [41–44]. For lung cancer,
macrophages as prognostic factor is still debated since the data
obtained from clinical studies seem controversial [9,45,46]. This
may be due to the infiltration of different types of macrophages.
Macrophages have been classified into two major groups: (a) M1
macrophages possess pro-inflammatory properties and (b) M2
macrophages have anti-inflammatory phenotype and promote
tumor progression. Within the tumor islet, both M1 and M2
macrophages could be present. Those macrophages associated
with favorable outcome in NSCLC patients were identified as M1
macrophages [47]. M2 macrophages may function in an opposite
way. Zeni et al. [48] reported that the percentage of IL-10-positive
macrophages within tumor islet was higher in patients with late
Figure 6. Proposed scheme of TP-mediated interactions between cancer cells and macrophages.
doi:10.1371/journal.pone.0054073.g006
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stage of NSCLC having lymph node metastasis than those patients
with early stage of NSCLC having no metastasis, and these
macrophages also predicted the worse overall survival. High
expression of IL-10 is one of the characteristic of M2 phenotype
[49], thus this study suggested that these macrophages behaved as
M2-polarized TAMs and thereafter promoted progression of
NSCLC.
We employed RAW 264.7 macrophages to study the interac-
tions between lung cancer cells and macrophages. RAW 264.7, a
murine macrophage cell line, can be polarized into either M1 or
M2 macrophages [50]. Interactions of RAW 264.7 macrophages
with human cancer cells such as lymphoma and breast cancer cells
have been reported in previous studies [51,52]. Furthermore,
human MCP-1 and mouse MCP-1 truncated at the C terminus
are highly homologous. Indeed, human MCP-1 even has a higher
chemotactic potency to murine monocytes than full length of
murine MCP-1 due to the less glycosylation of human MCP-1 C
terminus [53]. Therefore, RAW 264.7 macrophages can serve as
an appropriate cell line to study TP-mediated interactions between
lung cancer cells and macrophages.
Macrophages contribute to various aspects of cancer progres-
sion such as cancer cells proliferation, survival, invasion, metastasis
and angiogenesis. In this study, co-culture of macrophages with
A549 cells stimulated gene expressions of several MMPs and
VEGF by A549 cells. We previously reported that A549-TPa cells
induced tumor formation and angiogenesis in nude mice through
induction of VEGF expression [54]. We recently found that I-
BOP-induced invasion of A549-TPa cells was mediated by
increased expression of several MMPs such as MMP-1 and
MMP-9 [24]. Here, macrophages induced these genes, and thus
enhanced the effects of TP-mediated angiogenesis and invasion of
cancer cells. MCP-1 was also induced in A549 cells by co-culture
with macrophages forming a positive feedback loop that might
reinforce the recruitment of more macrophages to promote cancer
cell invasion. We did not examine the factors released by RAW
cells that may induce the expression of metastatic genes. However,
there is one report showing that breast cancer cells stimulated
production of inducible nitric oxide synthase and nitric oxide in
RAW 264.7 macrophages, which in turn induced MMP9 and
VEGF-A gene expression in breast cancer cells [52]. This is also
likely the mechanism by which RAW cells stimulated expression of
metastatic genes in lung cancer cells.
In addition to its indirect effects on tumor progression by
recruiting macrophages, MCP-1 has been shown to act directly on
cancer cells, such as prostate cancer, colon cancer and bladder
cancer cells to stimulate their migration and invasion [55–57]. In
this report we focused on the indirect effects of MCP-1 in
recruiting macrophages to enable invasion of lung cancer cells.
Whether macrophages can be induced to express MCP-1 acting
directly on lung cancer cell invasion remains to be determined.
Further studies on the induction of MCP-1 in macrophages and on
the direct effects of MCP-1 on the invasion of lung cancer cells will
be the focuses of our future reports.
Tumors are very heterogeneous and contain numerous
subpopulations of cells [58] that may express different levels of
TP. We show here that once TXA2 initiates a signaling cascade
leading to the release of MCP-1 from tumor cells expressing high
levels of TP, the subsequent recruited macrophages could increase
the invasion of tumor cells regardless of their TP levels. Therefore,
TP expands its influence on tumor progression through MCP-1-
mediated macrophage recruitment. In summary, TP-mediated
interactions between cancer cells and macrophages leading to an
increased invasive potential of carcinoma cells is illustrated in
Figure 6.
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